• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?

作者信息

Garattini Livio, Curto Alessandro, Freemantle Nick

机构信息

IRCCS Institute for Pharmacological Research 'Mario Negri', c/o Villa Camozzi, Ranica (BG), 24020, Italy.

UCL Medical School (Royal Free Campus), Royal Free Medical School, London, NW3 2PF, UK.

出版信息

Pharmacoeconomics. 2016 May;34(5):423-6. doi: 10.1007/s40273-015-0377-5.

DOI:10.1007/s40273-015-0377-5
PMID:26820147
Abstract
摘要

相似文献

1
Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?
Pharmacoeconomics. 2016 May;34(5):423-6. doi: 10.1007/s40273-015-0377-5.
2
[Risk sharing methods in middle income countries].[中等收入国家的风险分担方法]
Acta Pharm Hung. 2012;82(1):43-52.
3
Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?消费者道德风险下的药品价格管制。两部收费制、统一定价还是三级价格歧视？
Eur J Health Econ. 2004 Dec;5(4):324-9. doi: 10.1007/s10198-004-0237-2.
4
Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.药品再进口是否会缩小处方药的价格差异？来自欧盟的经验教训。
Health Serv Res. 2008 Aug;43(4):1308-24. doi: 10.1111/j.1475-6773.2008.00838.x. Epub 2008 Mar 12.
5
Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.药品的平行进口与定价：来自欧盟的证据
J Health Econ. 2004 Sep;23(5):1035-57. doi: 10.1016/j.jhealeco.2004.03.005.
6
The high cost of medicines in Ireland. Is it time to change the pricing mechanism?爱尔兰药品的高昂成本。是时候改变定价机制了吗？
Eur J Health Econ. 2004 Dec;5(4):341-4. doi: 10.1007/s10198-004-0245-2.
7
Convergence of decision rules for value-based pricing of new innovative drugs.新型创新药物基于价值定价的决策规则趋同
Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):209-13. doi: 10.1586/14737167.2015.972374. Epub 2014 Oct 18.
8
The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
Eur J Cancer. 2011 Jun;47(9):1285-6. doi: 10.1016/j.ejca.2011.04.002. Epub 2011 May 5.
9
Foreign free riders and the high price of US medicines.外国搭便车者与美国药品的高昂价格。
BMJ. 2005 Oct 22;331(7522):958-60. doi: 10.1136/bmj.331.7522.958.
10
Differential pricing of new pharmaceuticals in lower income European countries.欧洲低收入国家新药品的差异化定价。
Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):735-41. doi: 10.1586/14737167.2013.847367.

引用本文的文献

1
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting.诊断的健康经济学分析：设计和报告指南。
Pharmacoeconomics. 2021 Dec;39(12):1355-1363. doi: 10.1007/s40273-021-01104-8. Epub 2021 Nov 1.
2
Pricing vaccines and drugs in Europe: worth differentiating?欧洲疫苗和药品定价：是否值得区分？
Eur J Health Econ. 2021 Dec;22(9):1345-1348. doi: 10.1007/s10198-020-01211-x.
3
Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?欧洲的药品支出控制：是时候从定价转向预算了吗？

本文引用的文献

1
Market-access agreements for anti-cancer drugs.抗癌药物的市场准入协议。
J R Soc Med. 2015 May;108(5):166-70. doi: 10.1177/0141076814559626. Epub 2014 Dec 8.
2
Italian risk-sharing agreements on drugs: are they worthwhile?意大利药品风险分担协议：它们值得吗？
Eur J Health Econ. 2015 Jan;16(1):1-3. doi: 10.1007/s10198-014-0585-5.
3
What is value in health care?医疗保健中的价值是什么？
J R Soc Med. 2020 Mar;113(3):93-97. doi: 10.1177/0141076819894681. Epub 2019 Dec 20.
4
Comment on: 'The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study'.评《医院成本核算方法对成本效益分析的影响：一项案例研究》
Pharmacoeconomics. 2019 Oct;37(10):1301-1302. doi: 10.1007/s40273-019-00823-3.
5
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?多适应症定价：理论上可行，但实际中能奏效吗？
Pharmacoeconomics. 2018 Dec;36(12):1407-1420. doi: 10.1007/s40273-018-0716-4.
6
Pharmaceutical pricing conundrum: time to get rid of it?药品定价难题：是时候解决它了吗？
Eur J Health Econ. 2018 Nov;19(8):1035-1038. doi: 10.1007/s10198-018-0995-x.
7
Patient empowerment in Europe: is no further research needed?欧洲的患者赋权：是否无需进一步研究？
Eur J Health Econ. 2018 Jun;19(5):637-640. doi: 10.1007/s10198-018-0965-3.
8
Competition in pharmaceuticals: more product- than price-oriented?制药行业的竞争：更多以产品而非价格为导向？
Eur J Health Econ. 2018 Jan;19(1):1-4. doi: 10.1007/s10198-017-0932-4.
9
Market approval for drugs in the EU: time to change direction?欧盟药品的市场批准：是时候改变方向了吗？
Eur J Health Econ. 2017 Nov;18(8):933-936. doi: 10.1007/s10198-016-0863-5.
10
European Medicines Agency: leave the UK but remain the same.欧洲药品管理局：离开英国但保持不变。
J R Soc Med. 2016 Sep;109(9):324-5. doi: 10.1177/0141076816663559.
N Engl J Med. 2010 Dec 23;363(26):2477-81. doi: 10.1056/NEJMp1011024. Epub 2010 Dec 8.
4
Modeling in pharmacoeconomic studies: funding sources and outcomes.药物经济学研究中的模型构建：资金来源与结果。
Int J Technol Assess Health Care. 2010 Jul;26(3):330-3. doi: 10.1017/S0266462310000322.
5
Health technology assessment: for whom the bell tolls?
Eur J Health Econ. 2008 Nov;9(4):311-2. doi: 10.1007/s10198-008-0113-6.
6
Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.七个欧洲国家专利期内药品的定价与报销：一项比较分析
Health Policy. 2007 Aug;82(3):330-9. doi: 10.1016/j.healthpol.2006.11.004. Epub 2006 Nov 27.
7
Reference drug programs: effectiveness and policy implications.参比药物项目：有效性及政策影响
Health Policy. 2007 Apr;81(1):17-28. doi: 10.1016/j.healthpol.2006.05.001. Epub 2006 Jun 13.
8
Common methodological flaws in economic evaluations.经济评估中常见的方法学缺陷。
Med Care. 2005 Jul;43(7 Suppl):5-14. doi: 10.1097/01.mlr.0000170001.10393.b7.
9
Pricing medicines: theory and practice, challenges and opportunities.药品定价：理论与实践、挑战与机遇。
Nat Rev Drug Discov. 2005 Feb;4(2):121-30. doi: 10.1038/nrd1633.
10
The pharmaceutical industry--prices and progress.制药行业——价格与进展。
N Engl J Med. 2004 Aug 26;351(9):927-32. doi: 10.1056/NEJMhpr040117.